AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01453309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cell Saver
Description: Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
Study NCT01453309 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No Cell Saver
Description: Cell Saver will not be available during surgery
Study NCT02623296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205
Description: Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
Study NCT02623296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
Study NCT02623296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail of CYP450 substrates
Description: Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
Study NCT02623296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocktail of CYP450 substrates
Description: Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
Study NCT02107430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa arm post radiotherapy
Study NCT02107430 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa arm post radiotherapy
Study NCT02107430 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiotherapy
Description: radiotherapy
Study NCT03176277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475 3mg once daily
Description: Part A initial dose level
Study NCT03176277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475 6mg once daily
Description: Part A 2nd dose level
Study NCT03176277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475 10mg once daily
Description: Part A 3rd dose level
Study NCT03176277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475 6mg + Venetoclax (70-400mg)
Description: Part D ONO-7475 + Venetoclax Combination
Study NCT01379495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational program+telephone follow up
Description: burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
Study NCT02761239 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The NIM 3.0 Nerve Monitoring System
Description: Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
Study NCT01983319 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Constraint Induced Movement Therapy (CIMT)
Description: 2 weeks of CIMT
Study NCT03738176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sesame Oil
Description: Sesame oil(80 gm NaCMC-20 gmSesame oil)
Study NCT02668666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
Study NCT00041548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitric oxide for inhalation
Description: given at 20 ppm for 1 hour then weaned off over 4 hours
Study NCT00593502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir
Description: Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; > 40 kg, 75 mg twice daily, for 5 days
Study NCT00335829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00335829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT00335829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: embolization therapy
Study NCT00335829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery infusion
Study NCT06338111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA Sepsis Biomarkers dosage
Description: Observational
Study NCT02286726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02286726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT02981628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given Asparaginase Erwinia chrysanthemi
Study NCT02981628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02981628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and biopsy
Study NCT02981628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV
Study NCT02365584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
Study NCT00041548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: given at 20 ppm for one hour, then weaned off over four hours
Study NCT04399148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
Study NCT04399148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
Study NCT04046406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR neurography-guided cryoanalgesia
Description: Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
Study NCT02486887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemonitoring of weight, pulse and blood pressure
Study NCT02389712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
Study NCT02389712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed > 40mg.
Study NCT03611517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual rehabilitation programme
Description: The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
Study NCT03835000 — intervention group
Intervention type: PROCEDURE
Intervention: Orthopedic surgery
Description: before and after surgery, patient will need medical imaging to asses their conditions
Study NCT04399148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 MG
Description: Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
Study NCT02250235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health risk information
Study NCT00873769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine 10 mg
Description: Staccato Loxapine 10 mg, single dose
Study NCT03830814 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
Study NCT03906435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
Study NCT01904071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UFNB (Ultrasound guided femoral nerve block)
Description: Ultrasound Guided Femoral Nerve Block
Study NCT02242227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate
Study NCT02242227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent® Diskus®
Study NCT02242227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (HandiHaler®)
Study NCT02242227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (HandiHaler®)
Study NCT02242227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Diskus®)
Study NCT02242227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Diskus®)
Study NCT03657667 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ureteroscopy
Description: Endoscopic removal of kidney stones
Study NCT04436809 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel Node Biopsy
Description: Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection).
Study NCT04436809 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillary Dissection
Description: Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
Study NCT00478725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034, oral
Description: oral, 800 mg
Study NCT00478725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034, IV
Description: IV, 5 mg
Study NCT00478725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034, radiolabeled oral
Description: oral, 400 mg radiolabeled
Study NCT01278017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: ceftriaxone ,parenteral route, 50mg/kg/day divided twice
Study NCT00972829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 10 or 20 milligrams once or twice a week
Study NCT00972829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 5 or 10 milligrams
Study NCT03666975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIV 30 Hz
Description: LivMD LIV platform
Study NCT01361919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feedback During CPR Training and Testing
Description: Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool.
Study NCT01361919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Feedback During CPR Training and Testing
Description: Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool.
Study NCT01361919 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No Feedback Group
Description: A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur.
Study NCT01361919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feedback during CPR Training Not Testing
Description: Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
Study NCT03411265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-administered, e-health application
Description: RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention.
Study NCT04504370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
Study NCT04504370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
Study NCT03000374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
Study NCT03000374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
Study NCT03000374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
Study NCT03000374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Study NCT01904071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)
Study NCT01904071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVMS (IV Morphine)
Description: Intravenous Morphine
Study NCT01533870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: Oral 25 mg
Study NCT01533870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NKTR-118
Description: Oral 25 mg
Study NCT01533870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Oral 600 mg
Study NCT02694835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses with UV Absorber
Study NCT02694835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delefilcon A contact lenses
Study NCT03001843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Anesthesia of only Ketamine
Study NCT03001843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Narcotics
Description: The narcotic group will receive no ketamine but rather a more standard anesthetic
Study NCT02064959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temperature management Zoll Intravascular Temperature Management device
Study NCT02064959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature management Zoll Intravascular Temperature Management device
Study NCT04425629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab combination therapy
Description: Administered intravenously (IV) single dose
Study NCT01681381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tivoli® DES
Description: Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
Study NCT01681381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tivoli® DES
Description: Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
Study NCT01681381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Firebird2® DES
Description: The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.